Dartmouth Health Continuing Education for Professionals Home, CHaD Pediatric Lecture Series - GERD: Latest Guidelines and Controversies, 12/14/2021 8:00:00 AM - 12/14/2024 9:00:00 AM, This Pediatric Lecture Series will discuss important pediatric topics that may lead to the improvement of child health from an individual, health care system and/or societal level.
Presenter
Amer Al-Nimr, MD
Section Chief, Pediatric Gastroenterology
Assistant Professor of Pediatrics, Geisel School of Medicine at Dartmouth
Learning Outcome(s)
At the conclusion of this presentation, (at least 75% of) participants will be able to discuss GERD including the physiologic presentation of gastroesophageal reflux and treatment options for addressing GERD in the pediatric patient.
Disclosure
The activity director(s), planning committee member(s), speaker(s), author(s) or anyone in a position to control the content for this activity have reported NO financial relationship(s)* with ineligible companies**.
* A “financial relationship" includes employee, researcher (named as the PI), consultant, advisor, speaker, independent contractor (including contracted research), royalties or patent beneficiary, executive role, and/or an ownership interest (not including stocks owned in a managed portfolio).
** An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Bibliographic Resources
See presentation for bibliographic sources to allow for further study.
Presenter
Amer Al-Nimr, MD
Section Chief, Pediatric Gastroenterology
Assistant Professor of Pediatrics, Geisel School of Medicine at Dartmouth
Learning Outcome(s)
At the conclusion of this presentation, (at least 75% of) participants will be able to discuss GERD including the physiologic presentation of gastroesophageal reflux and treatment options for addressing GERD in the pediatric patient.
Disclosure
The activity director(s), planning committee member(s), speaker(s), author(s) or anyone in a position to control the content for this activity have reported NO financial relationship(s)* with ineligible companies**.
* A “financial relationship" includes employee, researcher (named as the PI), consultant, advisor, speaker, independent contractor (including contracted research), royalties or patent beneficiary, executive role, and/or an ownership interest (not including stocks owned in a managed portfolio).
** An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Bibliographic Resources
See presentation for bibliographic sources to allow for further study.
